XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues:        
Total revenue $ 3,299 $ 4,346 $ 6,531 $ 9,509
Costs and expenses:        
Cost of revenue 538 654 1,559 2,087
Research and development 13,028 5,956 36,061 24,560
General and administrative 4,871 5,653 16,396 17,249
Licensing 1,911 1,754 4,256 4,070
Revaluation of contingent consideration 100 800 1,900 3,800
Total costs and expenses 20,448 14,817 60,172 51,766
Loss from operations (17,149) (10,471) (53,641) (42,257)
Other income:        
Interest income 1,819 1,991 6,003 5,850
Non-cash royalty income 716 894 2,510 894
Total other income 2,535 2,885 8,513 6,744
Net loss $ (14,614) $ (7,586) $ (45,128) $ (35,513)
Net loss per share, basic $ (0.12) $ (0.11) $ (0.37) $ (0.5)
Net loss per share, diluted $ (0.12) $ (0.11) $ (0.37) $ (0.5)
Weighted average common shares outstanding, basic 122,619,311 71,381,731 122,531,032 71,249,813
Weighted average common shares outstanding, diluted 122,619,311 71,381,731 122,531,032 71,249,813
Other comprehensive income:        
Unrealized gain on marketable securities, net of tax of $0 $ 115 $ 890 $ 500 $ 533
Total other comprehensive income 115 890 500 533
Comprehensive loss (14,499) (6,696) (44,628) (34,980)
Contract research        
Revenues:        
Total revenue 485 645 1,372 1,926
Licensing        
Revenues:        
Total revenue $ 2,814 $ 3,701 $ 5,159 $ 7,583